ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 933

Inflammation in the Hippocampus Affects Insulin-like Growth Factor-1 Receptor Signaling and Contributes to Neurological Sequelae in Rheumatoid Arthritis

Karin Andersson1, Caroline Wasén1, Lina Juzokaite1, Malin C Erlandsson1,2, Anna Stokowska3, Lovisa Leifsdottir4, Marcela Pekna3, Milos Pekny3, Kjell Olmarker5, Rolf Heckemann6,7,8, Marie Kalm9 and Maria I Bokarewa2, 1Department of rheumatology and inflammation research, University of Gothenburg, Gothenburg, Sweden, 2Rheumatology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden, 3Department of Clinical Neuroscience, University of Gothenburg, Gothenburg, Sweden, 4Rheumatology Clinics, Sahlgrenska University Hospital, Gothenburg, Sweden, 5Department of Medical Chemistry and Cell Biology, University of Gothenburg, Gothenburg, Sweden, 6Med Tech West at Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden, 7Department of Medical Radiation Science, University of Gothenburg, Gothenburg, Sweden, 8Faculty of Medicine, Imperial College London, London, United Kingdom, 9Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Insulin-like growth factor, neurology, pain, psychological well-being and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: 3S107 ACR Abstract: RA–Etiology & Pathogenesis I (928–933)

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: The central nervous system is not the primary target in rheumatoid arthritis (RA). However, neuropsychiatric symptoms including pain, depression and anxiety are common and may be critical for patients’ quality of life. The aim of the present study was to investigate how insulin-like growth factor receptor (IGF1R) signaling in RA associates with morphometric changes of the brain, and ultimately impairment of their functional ability.

Methods: Arthritis was induced in DBA/1 mice by collagen II and the RA-mice were filmed to evaluate behavioral changes. IGF1R was inhibited with short hairpin RNA. At termination, brains were analyzed by quantitative PCR and immunohistofluorescence. 15 RA patients, all of them satisfying ACR classification criteria, underwent magnetic resonance imagining (MRI) for volumetric analysis of hippocampus at 3 Tesla and processed with brain morphometry software (MAPER). Physical functioning was assessed by the Health Assessment Questionnaire (HAQ). Pain threshold was measured by algometer. Statistical analysis included the Mann-Whitney U-test and Spearman’s rank correlation coefficient.

Results: Evaluation of MRI and physical functioning in RA patients revealed that smaller hippocampus volume was linked with exaggerated response of induced pain (p=0.0006), higher functional disability (HAQ, p= 0.009), and lower serum levels of IGF1 (p=0.05). RA-mice had signs of inflammation in the hippocampus, presented by higher density of IBA1+ microglia and higher transcription of microglia activation marker CD68 (p= 0.0006) and interleukin-1β (p= 0.002). Enrichment of microglia was observed in the pyramidal layer of cornu ammoni (CAsp, p= 0.02) and the molecular layer of the dentate gyrus (DGmo, p= 0.02). This coincided with inhibitory phosphorylation of insulin receptor substrate-1 (IRS1) in the subgranular layer of DG (DGsg, p= 0.03) and CAsp (p= 0.05), and up-regulation of IGF1R in the CAsp (p= 0.03). These changes reproduce the molecular signature of IGF1/insulin resistance. DGsg, the site of life-long neurogenesis, became thinner (p= 0.03) and the reduced thickness correlated with a smaller number of DCX+ developing neurons in this area (r= 0.7, p= 0.005). There was also a reduction in the total hippocampus area of RA-mice (p= 0.02). Inhibition of IGF1R in RA-mice led to reduced inhibitory phosphorylation of IRS1 (p= 0.004) and partial improvement of neurogenesis, seen as an increased number of GFAP+ neuronal stem cells in DGsg (p= 0.02).

Conclusion: We offer a mechanistic link between pain perception in RA and reduced hippocampal volume. Our experimental study demonstrates that inflammation reproduce the molecular signature of IGF1/insulin resistance, which leads to inadequate maintenance of hippocampal neurons and consequently reduced hippocampal volume.


Disclosure: K. Andersson, None; C. Wasén, None; L. Juzokaite, None; M. C. Erlandsson, None; A. Stokowska, None; L. Leifsdottir, None; M. Pekna, None; M. Pekny, None; K. Olmarker, None; R. Heckemann, None; M. Kalm, None; M. I. Bokarewa, None.

To cite this abstract in AMA style:

Andersson K, Wasén C, Juzokaite L, Erlandsson MC, Stokowska A, Leifsdottir L, Pekna M, Pekny M, Olmarker K, Heckemann R, Kalm M, Bokarewa MI. Inflammation in the Hippocampus Affects Insulin-like Growth Factor-1 Receptor Signaling and Contributes to Neurological Sequelae in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/inflammation-in-the-hippocampus-affects-insulin-like-growth-factor-1-receptor-signaling-and-contributes-to-neurological-sequelae-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inflammation-in-the-hippocampus-affects-insulin-like-growth-factor-1-receptor-signaling-and-contributes-to-neurological-sequelae-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology